Companies: 10,795·Total market cap: $144.5T
EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPTNASDAQHealthcare● Active
$11.52
$-0.26(-2.20%)
Market Cap$965902058
P/E Ratio
52W High$19.11
52W Low$7.94
SEC Filings

EyePoint Pharmaceuticals, Inc. (EYPT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001314102 · EYPT · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
SCHEDULE 13G
Latest Form
2026-06-03
Most Recent
2005
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001314102 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-05
Fiscal Year End
Mar 5, 2026
Accession No.
0001193125-26-093917
Primary Document
eypt-20251231.htm
Source: data.sec.gov · CIK 0001314102 · Accession 0001193125-26-093917

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-05-14Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-06-03
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
8-KCurrent Report
8-K
2026-05-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-13
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-06
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-27
View
DEF 14AProxy Statement
DEF 14A
2026-04-27
View
8-KCurrent Report
8-K
2026-04-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-20
View
10-KAnnual Report
10-K
2026-03-05
View
8-KCurrent Report
8-K
2026-03-04
View
8-KCurrent Report
8-K
2026-03-02
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-24
View
Showing 1–15 of 584 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001314102  |  Exchange: NASDAQ · Healthcare

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2005. As a Healthcare sector company with CIK 0001314102, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is EyePoint Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent EyePoint Pharmaceuticals, Inc. 10-K was filed on 2026-03-05 for fiscal year ending 2026. Historical EYPT 10-K annual reports are available from 2009 through 2026.

Investors researching EyePoint Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

EYPT SEC Filings · 8 questions

EyePoint Pharmaceuticals, Inc. (EYPT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. EyePoint Pharmaceuticals, Inc.'s CIK is 0001314102.

EYPT SEC filingsEyePoint Pharmaceuticals, Inc. SEC documentsfind EYPT 10-K